PharmiWeb Recruiter Blog

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers.

- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities

• Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion
• Proposed combination enhances Pfizer’s position as a leading company in Oncology
• Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
• Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
• Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today

NEW YORK & BOTHELL, Wash.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

BALLERUP, DENMARK and DUBLIN, IRELAND — 10 March, 2023 — LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Bagsværd, Denmark, 7 March 2023 – Novo Nordisk today announced the following changes in Executive Management.

Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational software. The pilot project, supported by esqLABS, Dynamic42, Placenta Lab of Jena University Hospital, and Bayer’s Consumer Health Division aims to generate clinically relevant data, a key step in evaluating new drug candidates in preclinical research.

Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development activities.  

COPENHAGEN, Denmark, March 1, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that ten new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups within human and planetary health.

Berkshire, UK, 28^th February 2023 – PharmiWeb.Jobs, the leading global Life Science job board, today announces a new portfolio of recruitment training courses for those hiring within the Life Science industry.